Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent...

Area of Science:

• Microbiology
• Gastroenterology
• Pharmacology

Background:

• Clostridioides difficile infection (CDI) recurrence is linked to low gut microbial diversity and altered bile acid metabolism.
• Understanding these factors in first-time vs. multiply recurrent CDI (frCDI vs. mrCDI) is crucial for effective treatment strategies.

Purpose of the Study:

• To compare gastrointestinal microbiome and bile acid profiles in patients with frCDI and mrCDI.
• To evaluate the efficacy of fecal microbiota spores, live-brpk (VOS) in a Phase 3 trial (ECOSPOR IV).

Main Methods:

• Post hoc analysis of a Phase 3 trial involving patients receiving VOS after standard antibiotics.
• Analysis of stool samples for microbiome diversity (whole metagenomic sequencing) and bile acid concentrations (LC-MS/MS) at baseline and week 1 post-dosing.

Main Results:

• Recurrent CDI (rCDI) rates were low and similar for frCDI (6.5%) and mrCDI (9.7%) patients through week 8.
• Baseline microbial diversity was low and comparable between frCDI and mrCDI groups.
• VOS treatment increased microbial diversity and secondary bile acids while decreasing primary bile acids, with minimal differences between groups at week 1.

Conclusions:

• Microbiome disruption is a common factor in both frCDI and mrCDI.
• Antibiotics followed by live microbiome therapy (VOS) appears to be an optimal strategy for rCDI, irrespective of prior recurrence history.